Format

Send to

Choose Destination
Bone Marrow Transplant. 2018 Nov 1. doi: 10.1038/s41409-018-0373-4. [Epub ahead of print]

Hematopoietic stem cell transplantation for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia in first remission: a position statement of the European Working Group for Adult Acute Lymphoblastic Leukemia (EWALL) and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation (EBMT).

Author information

1
Maria Sklodowska-Curie Institute-Cancer Center, Gliwice Branch, Gliwice, Poland. sgiebel@io.gliwice.pl.
2
University Hospitals Bristol National Health Service Foundation Trust, Bristol, UK.
3
Hopital St. Louis, Paris, France.
4
CHU Sart-Tilman, University of Liege, Liege, Belgium.
5
Sapienza University, Rome, Italy.
6
San Raffaele Scientific Institute, Milan, Italy.
7
Erasmus MC Cancer Institute University Medical Center, Rotterdam, The Netherlands.
8
University Hospital, Brno, Czechia.
9
IDIBAPS, Hospital Clinic, Barcelona, Spain.
10
North London Cancer Network, Univ. College London Hosp, London, UK.
11
EBMT Acute Leukemia Working Party Office, Paris, France.
12
Hospital Saint-Antoine, Paris, France.
13
Maria Sklodowska-Curie Institute-Cancer Center, Gliwice Branch, Gliwice, Poland.
14
Uppsala University, Uppsala, Sweden.
15
University Hospital, Goethe University, Frankfurt, Germany.
16
FGBU Hematology Research Center, Russia Federation Ministry of Public Health, Moscow, Russia.
17
ICO-Hospital Germans Trias I Pujol, Jose Carreras Research Institute, Badalona, Spain.
18
Vanderbilt University Medical Center, Nashville, USA.
19
Klinikum Augsburg, Ludwig-Maximilians-Universitaet, Munich-Augsburg, Germany.
20
Helsinki University Hospital, Helsinki, Finland.
21
Chaim Sheba Medical Center, Tel-Hashomer, Israel.

Abstract

Allogeneic hematopoietic stem cell transplantation (HSCT) in first complete remission is a standard of care for adult patients with Philadelphia chromosome (Ph)-negative acute lymphoblastic leukemia (ALL) and high risk of relapse. However, the stratification systems vary among study groups. Inadequate response at the level of minimal residual disease is the most commonly accepted factor indicating the need for alloHSCT. In this consensus paper on behalf of the European Working Group for Adult Acute Lymphoblastic Leukemia and the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation, we summarize available evidence and reflect current clinical practice in major European study groups regarding both indications for HSCT and particular aspects of the procedure including the choice of donor, source of stem cells and conditioning. Finally, we propose recommendations for daily clinical practice as well as for planning of prospective trials.

PMID:
30385870
DOI:
10.1038/s41409-018-0373-4

Supplemental Content

Full text links

Icon for Nature Publishing Group
Loading ...
Support Center